Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC
– V2ACT Therapeutics™, LLC is a joint venture between Genelux Corporation and TVAX Biomedical, Inc….
OKSPOT Unveils Privacy-Focused Crypto Exchange for Global Traders With No-KYC Registration and Monero Support
Mambu and Mastercard expand cross-border payment capabilities for banks across APAC
Indonesia’s ITS Celebrates 66th Anniversary and Officially Closes KSTI 2026
Shaping the Future Together: Voices from Around the World at the III International Symposium ‘Creating the Future’ in Russia
The UAE’s AI Adoption Is a World Record. Paying for It Is Another Story